

May 05, 2022

To,
National Stock Exchange of India Limited
Exchange Plaza
Bandra Kurla Complex,
Bandra (E), Mumbai - 400 051

BSE Limited
Phiroze Jeejeeboy Towers
Dalal Street,
Mumbai- 400 001

Scrip Symbol: THYROCARE

Script Code: 539871

Dear Sir/Madam,

Sub: Joining of Mr. Rahul Guha as the Managing Director & Chief Executive Officer – Intimation under Regulation 30 read with Part A to Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

--o--

Please refer to our letter dated February 07, 2022 filed with you under the provisions of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with the Schedule III intimating that Mr. Rahul Guha has been appointed as the Managing Director & Chief Executive Officer of the Company and that he would be joining in the month of May 2022.

We wish to inform you that Mr. Rahul Guha has taken charge as the Managing Director & Chief Executive Officer with effect from Wednesday, May 04, 2022.

We wish to add that Mr. Rahul Guha will also function as the Managing Director & CEO of Nuclear Healthcare Limited, our wholly owned subsidiary.

Mr. Dharmil Sheth, who was appointed as the Managing Director for the interim period to comply with the provisions of Sec. 203 (4) of the Companies Act, 2013, has demitted office effective from Wednesday, May 04, 2022 and will continue to be a Non-Executive, Non-Independent Director of the Company.

This is for your information and records.

Yours Faithfully,
For Thyrocare Technologies Limited,



Ramjee Dorai
Company Secretary and Compliance Officer



Thyrocare Technologies Limited